Dennis Chen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Corporate Officer/Principal | - | - |
Career history of Dennis Chen
Former positions of Dennis Chen
| Companies | Position | Start | End |
|---|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | - | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Statistics
International
| United States | 3 |
| Canada | 2 |
Operational
| Corporate Officer/Principal | 3 |
Sectoral
| Health Technology | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| GERON CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Dennis Chen
- Experience
